Patents by Inventor Linli Li

Linli Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250064789
    Abstract: A class of ketoamide derivatives and pharmaceutical uses thereof are provided. Specifically provided are the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or a deuterated compound thereof. The compound can effectively inhibit the activity of SARS-CoV-2 Mpro, and can be used in the manufacturer of SARS-CoV-2 Mpro inhibitors, blocking the replication and transcription of SARS-CoV-2 virus in patients. The compound can be used in preparing SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 medicaments, as well as the medicaments for preventing and/or treating Corona Virus Disease 2019 (COVID-19).
    Type: Application
    Filed: February 15, 2023
    Publication date: February 27, 2025
    Inventors: Shengyong YANG, Linli LI
  • Publication number: 20240351199
    Abstract: A method for intelligently controlling a mechanical arm includes building a twin model of a mechanical arm, and extracting a state parameter and an action parameter corresponding to task characteristics from the twin model; determining a reward function corresponding to the task characteristics; training a twin delayed deep deterministic policy gradient (TD3) reinforcement learning model; simulating in the twin model based on a physical state parameter of the mechanical arm by using the TD3 reinforcement learning model, to obtain a controllable parameter; and controlling the mechanical arm to execute a corresponding task by using the controllable parameter. The TD3 reinforcement learning model is built based on the state parameter and the action parameter corresponding to the task characteristics and the reward function corresponding to the task characteristics, which can adapt to a dynamically changing environment and requirements for multiple tasks.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 24, 2024
    Applicant: ZHENGZHOU UNIVERSITY OF LIGHT INDUSTRY
    Inventors: Hao LI, Gen LIU, Yonglei WU, Haoqi WANG, Linli LI, Xiaoyu WEN, Shizhong WEI, Yuyan ZHANG, Like ZHANG, Weifei GUO
  • Publication number: 20240354657
    Abstract: A method for digital twin virtual-reality synchronization mapping of a mechanical arm comprises acquiring a virtual mechanical arm model built based on an actual mechanical arm in a virtual environment, where the virtual mechanical arm model is configured to map the actual mechanical arm; acquiring real motion information collected when the actual mechanical arm moves; constructing a training set and a test set based on the real motion information; training a target multilayer perceptron model based on the training set, and testing the target multilayer perceptron model based on the test set, where the target multilayer perceptron model is configured to predict a motion of the virtual mechanical arm model in the virtual environment; and deploying the target multilayer perceptron model on the actual mechanical arm when the target multilayer perceptron model meets a preset condition. According to this method, operation accuracy and efficiency of the mechanical arm are improved.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 24, 2024
    Applicant: ZHENGZHOU UNIVERSITY OF LIGHT INDUSTRY
    Inventors: Hao LI, Gen LIU, Xingyou HE, Haoqi WANG, Linli LI, Xiaoyu WEN, Shizhong WEI, Yuyan ZHANG, Weifei GUO, Wenchao YANG
  • Publication number: 20230365546
    Abstract: Provided are a 5-substituted indole 3-amide derivative, a preparation method and a use thereof, belonging to the field of medicine. A compound represented by formula I or a pharmaceutically acceptable salt thereof is provided. This type of compound can significantly inhibit the activity of RIPK1 kinase, has high selectivity and excellent safety, serves as a RIPK1 kinase inhibitor, and can be used as a potential therapeutic drug for inflammation, immune diseases, tumors and neurodegenerative diseases. TNF?-induced SIRS model experiments proved that the compound can inhibit a RIPK1 kinase in vivo. Pharmacokinetic results showed that this series of compounds has excellent pharmacokinetic properties, thus providing a novel strategy and means for disease treatments targeting RIPK1.
    Type: Application
    Filed: September 2, 2021
    Publication date: November 16, 2023
    Applicant: ORIGIANT PHARMACEUTICAL CO., LTD
    Inventors: Shengyong YANG, Linli LI
  • Publication number: 20230144619
    Abstract: Provided in the present invention are a salt of an arylaminopurine derivative represented by Formula (2), a preparation method therefor and the use thereof. The salt obtained in the present invention has good crystallinity and significantly improved solubility relative to that in the free form, and the preferred salt and crystal form have low hygroscopicity and can exist stably. Therefore, compared with the free form of arylaminopurine derivatives or other salts, it is easier to prepare same into a medicine.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 11, 2023
    Applicant: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
    Inventors: Dehua Ji, Shengyong Yang, Xiaofeng Guo, Chen Zhang, Linli Li, Yuxiu Ma, Xiaowei Sun, Qiaoli Cui, Feng Guo, Haohao Zhang
  • Publication number: 20230021442
    Abstract: A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Applicant: CHENGDU HENGHAO INNOVATIVE SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Shengyong YANG, Linli LI
  • Patent number: 11440909
    Abstract: 10H-phenothiazine derivatives capable of inhibiting ferroptosis has structural formula (I). The derivatives, pharmaceutically acceptable salts thereof, crystal forms thereof, or solvates thereof exhibit inhibitory effect on ferroptosis, and therapeutic effect on a rat model of focal cerebral ischemia and thus can be used as a main active ingredient in the preparation of ferroptosis inhibitors. The compounds and the inhibitors prepared by the compounds have good medicinal potential and are expected to be used as drug candidates for the treatment of stroke.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: September 13, 2022
    Assignee: CHENGDU HENGHAO INVESTMENT CO. LIMITED
    Inventors: Shengyong Yang, Linli Li
  • Patent number: 11149008
    Abstract: The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone deacetylases, has remarkable inhibition effects on cancer cells, and provides a new choice of drugs used for the clinic treatment and diseases related to the abnormal activity of histone deacetylases.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: October 19, 2021
    Inventors: Jin Li, Xueming Li, Dengfeng Dou, Jinqiao Wan, Wei Zhang, Jingming Li, Yan Lan, Linli Li
  • Publication number: 20210040079
    Abstract: 10H-phenothiazine derivatives capable of inhibiting ferroptosis has structural formula (I). The derivatives, pharmaceutically acceptable salts thereof, crystal forms thereof, or solvates thereof exhibit inhibitory effect on ferroptosis, and therapeutic effect on a rat model of focal cerebral ischemia and thus can be used as a main active ingredient in the preparation of ferroptosis inhibitors. The compounds and the inhibitors prepared by the compounds have good medicinal potential and are expected to be used as drug candidates for the treatment of stroke.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Shengyong YANG, Linli LI
  • Publication number: 20190031612
    Abstract: The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone deacetylases, has remarkable inhibition effects on cancer cells, and provides a new choice of drugs used for the clinic treatment and diseases related to the abnormal activity of histone deacetylases.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 31, 2019
    Inventors: Jin Li, Xueming Li, Dengfeng Dou, Jinqiao Wan, Wei Zhang, Jingming Li, Yan Lan, Linli Li
  • Patent number: D1038199
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: August 6, 2024
    Inventor: Linli Li
  • Patent number: D1042585
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: September 17, 2024
    Inventor: Linli Li
  • Patent number: D1060459
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: February 4, 2025
    Assignee: Shenzhen Puairuide Technology Co., Ltd.
    Inventor: Linli Li
  • Patent number: D1062967
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: February 18, 2025
    Assignee: Shenzhen Puairuide Technology Co., Ltd.
    Inventor: Linli Li